Last reviewed · How we verify
Phase 3 NOMAC-E2 "Batch A"
NOMAC-E2 is a combined oral contraceptive containing norethisterone acetate (progestin) and ethinyl estradiol (estrogen) that prevents pregnancy through ovulation suppression and cervical mucus thickening.
NOMAC-E2 is a combined oral contraceptive containing norethisterone acetate (a progestin) and ethinyl estradiol (an estrogen) that prevents pregnancy through ovulation suppression and cervical mucus thickening. Used for Contraception in women of reproductive age.
At a glance
| Generic name | Phase 3 NOMAC-E2 "Batch A" |
|---|---|
| Also known as | SCH900121 |
| Sponsor | Organon and Co |
| Drug class | Combined oral contraceptive |
| Target | Progesterone receptor, estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Gynecology |
| Phase | FDA-approved |
Mechanism of action
The progestin component suppresses the luteinizing hormone (LH) surge required for ovulation, while the estrogen component stabilizes the endometrium and enhances contraceptive efficacy. Together, these hormones also increase cervical mucus viscosity, creating a barrier to sperm penetration and reducing the likelihood of fertilization.
Approved indications
- Contraception in women of reproductive age
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phase 3 NOMAC-E2 "Batch A" CI brief — competitive landscape report
- Phase 3 NOMAC-E2 "Batch A" updates RSS · CI watch RSS
- Organon and Co portfolio CI